Financial Performance - Core sales increased by 6% CER to $532 million, exceeding the outlook of ≥5%[5,9] - Net sales reached $533 million, a 5% CER increase compared to Q3 2024[5,7] - Adjusted diluted EPS was $0.61 CER, a 7% CER increase, surpassing the outlook of ≥$0.58 CER[5] - Adjusted operating income margin remained steady at 29.6%[5,24] - Operating cash flow for 9M 2025 was $466 million, a 3% decrease[5] Product and Portfolio Developments - QIAstat-Dx and QuantiFERON both experienced 11% CER growth, leading the portfolio[5,8] - Sample technologies showed a 3% CER growth[5,8] - QIAcuity digital PCR and QDI delivered solid contributions[5,8] - Parse Biosciences acquisition is expected to contribute ~$40 million in sales in 2026[22] Outlook and Capital Allocation - The company reaffirmed its 2025 net sales outlook of +4-5% CER (+5-6% CER core growth)[5] - The company increased its adjusted diluted EPS outlook to ~$2.38 CER (previously ~$2.35 CER)[5] - At least $1 billion of returns to shareholders is planned for 2024-28 (absent M&A)[14] - $500 million share repurchase program is authorized for completion in January 2026[15]